NEW YORK (Reuters Health) Oct 14 –
Vaccination with autologous tumor-derived peptide complexes can induce a complete clinical response in patients with metastatic melanoma, according to a recent report. Moreover, such treatment appears to be well tolerated with no significant toxic effects.
The vaccine, which consists of autologous tumor-derived heat shock protein gp96-peptide complexes (HSPPC-96), is produced by Woburn, Massachusetts-based Antigenics, Inc. under the trade name Oncophage
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!